Document Detail


Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen.
MedLine Citation:
PMID:  2436124     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Authors describe the results obtained with weekly low-dose (20 or 30 mg/total) of intravenous bolus epirubicin, used as second line chemotherapy, after CMF, in 29 advanced breast carcinoma patients. 29% objective response rate (1 complete + 6 partial responses) has been observed in 24 evaluable patients, with median response duration of 4 months (range 1-7+). The discrete response rate and the minimal incidence of side effects call for further studies and more extensive evaluation of epirubicin given alone or in combination through this new treatment schedule.
Authors:
G Beretta; C Locatelli; D Tabiadon; R Labianca; P Fraschini; G Luporini
Related Documents :
21562744 - Overall survival after resection for colon cancer in a national cohort study was advers...
21601474 - Role of chemotherapy in the management of vulvar carcinoma.
7517154 - Phase i study of taxol, doxorubicin, plus granulocyte-colony stimulating factor in pati...
21694854 - Gastric cancer and the search for a good prognostic classification: a challenge.
12849664 - Are lipid-lowering drugs also antiarrhythmic drugs? an analysis of the antiarrhythmics ...
2395134 - Cosmetic results of early breast carcinoma treated with wide local excision, external b...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Oncology     Volume:  44     ISSN:  0030-2414     ISO Abbreviation:  Oncology     Publication Date:  1987  
Date Detail:
Created Date:  1987-05-15     Completed Date:  1987-05-15     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0135054     Medline TA:  Oncology     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  6-12     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Breast Neoplasms / drug therapy*,  pathology
Doxorubicin / administration & dosage*,  adverse effects,  therapeutic use
Drug Administration Schedule
Epirubicin
Female
Heart Diseases / chemically induced
Humans
Middle Aged
Neoplasm Metastasis
Palliative Care
Chemical
Reg. No./Substance:
23214-92-8/Doxorubicin; 56420-45-2/Epirubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The species-specific nature of the ototoxicity of dihydrostreptomycin in the patas monkey.
Next Document:  The value of calcofluor white in the diagnosis of mycotic and Acanthamoeba infections of the eye and...